open access

Vol 7, No 4 (2018)
ORIGINAL ARTICLES
Published online: 2018-09-11
Get Citation

Pentraxin 3 and retinopathy among type 2 diabetic patients in relation to carotid atherosclerosis and systolic and diastolic cardiac function — a pilot study

Artur Chodkowski, Katarzyna Nabrdalik, Hanna Kwiendacz, Andrzej Tomasik, Wojciech Bartman, Janusz Gumprecht
DOI: 10.5603/DK.2018.0016
·
Clinical Diabetology 2018;7(4):196-202.

open access

Vol 7, No 4 (2018)
ORIGINAL ARTICLES
Published online: 2018-09-11

Abstract

Introduction. Diabetic retinopathy (DR) is the leading cause of vision loss worldwide. Global prevalence of any diabetic retinopathy is assessed to be 35.4%. Several studies proved that chronic low-grade inflammation may be involved in the pathogenesis of DR. Some studies indicate that macroangiopathic diabetic complications may be associated with microangiopathic ones that is why a “common soil” mechanism of diabetic micro- and macroangiogpathy has been proposed. The aim of this study was to evaluate the association of pentraxin 3 (PTX3), an inflammation’s biomarker, with diabetic retinopathy in relation to atherosclerosis in carotid arteries and systolic and diastolic cardiac function.

Material and methods. 43 eligible patients with type 2 diabetes were enrolled into the study and dived into two groups on the basis of presence or lack of retinopathy. Anthropometric, biochemical and carotid as well as cardiac ultrasound parameters were analyzed.

Results. There was no direct association between PTX3 concentration and the presence of diabetic retinopathy, but there was a significant correlation between PTX3 and HbA1c value, age and IMT (intima media thickness) in carotid arteries among patients with diabetic retinopathy.

Conclusions. There is a great need for further, larger, studies on inflammatory biomarkers such as PTX3 and micro and macrovascular complications of diabetes mellitus in order to detect predisposed patients early enough to implement early therapeutic intervention of this complication.

Abstract

Introduction. Diabetic retinopathy (DR) is the leading cause of vision loss worldwide. Global prevalence of any diabetic retinopathy is assessed to be 35.4%. Several studies proved that chronic low-grade inflammation may be involved in the pathogenesis of DR. Some studies indicate that macroangiopathic diabetic complications may be associated with microangiopathic ones that is why a “common soil” mechanism of diabetic micro- and macroangiogpathy has been proposed. The aim of this study was to evaluate the association of pentraxin 3 (PTX3), an inflammation’s biomarker, with diabetic retinopathy in relation to atherosclerosis in carotid arteries and systolic and diastolic cardiac function.

Material and methods. 43 eligible patients with type 2 diabetes were enrolled into the study and dived into two groups on the basis of presence or lack of retinopathy. Anthropometric, biochemical and carotid as well as cardiac ultrasound parameters were analyzed.

Results. There was no direct association between PTX3 concentration and the presence of diabetic retinopathy, but there was a significant correlation between PTX3 and HbA1c value, age and IMT (intima media thickness) in carotid arteries among patients with diabetic retinopathy.

Conclusions. There is a great need for further, larger, studies on inflammatory biomarkers such as PTX3 and micro and macrovascular complications of diabetes mellitus in order to detect predisposed patients early enough to implement early therapeutic intervention of this complication.

Get Citation

Keywords

diabetes type 2; diabetic retinopathy; pentraxin 3

About this article
Title

Pentraxin 3 and retinopathy among type 2 diabetic patients in relation to carotid atherosclerosis and systolic and diastolic cardiac function — a pilot study

Journal

Clinical Diabetology

Issue

Vol 7, No 4 (2018)

Pages

196-202

Published online

2018-09-11

DOI

10.5603/DK.2018.0016

Bibliographic record

Clinical Diabetology 2018;7(4):196-202.

Keywords

diabetes type 2
diabetic retinopathy
pentraxin 3

Authors

Artur Chodkowski
Katarzyna Nabrdalik
Hanna Kwiendacz
Andrzej Tomasik
Wojciech Bartman
Janusz Gumprecht

References (40)
  1. Drakopoulou M, Toutouzas K, Michelongona A, et al. Vulnerable plaque and inflammation: potential clinical strategies. Curr Pharm Des. 2011; 17(37): 4190–4209.
  2. Pant S, Deshmukh A, Gurumurthy GS, et al. Inflammation and atherosclerosis--revisited. J Cardiovasc Pharmacol Ther. 2014; 19(2): 170–178.
  3. Papatheodorou K, Banach M, Bekiari E, et al. Complications of Diabetes 2017. J Diabetes Res. 2018; 2018: 3086167.
  4. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82(11): 844–851.
  5. Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic Retinopathy. Prim Care. 2015; 42(3): 451–464.
  6. Negi A, Vernon SA. An overview of the eye in diabetes. J R Soc Med. 2003; 96(6): 266–272.
  7. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4): 773–795.
  8. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11(2): 98–107.
  9. Mantovani A, Garlanda C, Bottazzi B, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006; 45(5): 326–330.
  10. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. http://www.diabetesatlas.org/.
  11. Breviario F. d’Aniello EM. Golay J. et al.. J Biol Chem. 1992; 267(31): –22197. http://www.jbc.org/content/267/31/22190.
  12. Szuszkiewicz-Garcia MM, Davidson JA. Cardiovascular disease in diabetes mellitus: risk factors and medical therapy. Endocrinol Metab Clin North Am. 2014; 43(1): 25–40.
  13. Gewurz H, Zhang XH, Lint TF. Structure and function of the pentraxins. Curr Opin Immunol. 1995; 7(1): 54–64.
  14. Lech M, Rommele C, Anders HJ. Pentraxins in nephrology: C-reactive protein, serum amyloid P and pentraxin-3. Nephrol Dial Transplant. 2013; 28(4): 803–811.
  15. Speeckaert MM, Speeckaert R, Carrero JJ, et al. Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease. J Clin Immunol. 2013; 33(5): 881–890.
  16. Ghosh P, Sahoo R, Vaidya A, et al. Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev. 2015; 36(3): 272–288.
  17. Iwasaki A, Medzhitov R, Iwasaki A, et al. Regulation of adaptive immunity by the innate immune system. Science. 2010; 327(5963): 291–295.
  18. Bottazzi B, Garlanda C, Salvatori G, et al. Pentraxins as a key component of innate immunity. Curr Opin Immunol. 2006; 18(1): 10–15.
  19. Zhou W, Hu W. Serum and Vitreous Pentraxin 3 Concentrations in Patients with Diabetic Retinopathy. Genet Test Mol Biomarkers. 2016; 20(3): 149–153.
  20. Yang HS, Woo JE, Lee SJu, et al. Elevated plasma pentraxin 3 levels are associated with development and progression of diabetic retinopathy in Korean patients with type 2 diabetes mellitus. Invest Ophthalmol Vis Sci. 2014; 55(9): 5989–5997.
  21. Nabrdalik K, Chodkowski A, Bartman W, et al. Pentraxin 3 and atherosclerosis among type 2 diabetic patients. Open Life Sciences. 2017; 12(1).
  22. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015; 2: 17.
  23. Bartman W, Nabrdalik K, Kwiendacz H, et al. Association between carotid plaque score and microvascular complications of type 2 diabetes. Pol Arch Intern Med. 2017; 127(6): 418–422.
  24. Massengill MT, Ahmed CM, Lewin AS, et al. Neuroinflammation in Retinitis Pigmentosa, Diabetic Retinopathy, and Age-Related Macular Degeneration: A Minireview. Adv Exp Med Biol. 2018; 1074: 185–191.
  25. Gökşen D, Levent E, Kar S, et al. Serum adiponectin and hsCRP levels and non-invasive radiological methods in the early diagnosis of cardiovascular system complications in children and adolescents with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 2013; 5(3): 174–181.
  26. Yu HI, Sheu WHH, Song YM, et al. C-reactive protein and risk factors for peripheral vascular disease in subjects with Type 2 diabetes mellitus. Diabet Med. 2004; 21(4): 336–341.
  27. Jenny NS, Arnold AM, Kuller LH, et al. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009; 29(4): 594–599.
  28. Jylhävä J, Haarala A, Kähönen M, et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol. 2011; 164(2): 211–217.
  29. Jenny NS, Blumenthal RS, Kronmal RA, et al. Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost. 2014; 12(6): 999–1005.
  30. Vilahur G, Badimon L. Biological actions of pentraxins. Vascul Pharmacol. 2015; 73: 38–44.
  31. Napoleone E. Long Pentraxin PTX3 Upregulates Tissue Factor Expression in Human Endothelial Cells: A Novel Link Between Vascular Inflammation and Clotting Activation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2002; 22(5): 782–787.
  32. Koga S, Ikeda S, Yoshida T, et al. Elevated levels of systemic pentraxin 3 are associated with thin-cap fibroatheroma in coronary culprit lesions: assessment by optical coherence tomography and intravascular ultrasound. JACC Cardiovasc Interv. 2013; 6(9): 945–954.
  33. Polak JF, Pencina MJ, Pencina KM, et al. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med. 2011; 365(3): 213–221.
  34. Polak JF, Szklo M, Kronmal RA, et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2013; 2(2): e000087.
  35. Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000; 102(6): 636–641.
  36. Latini R, Maggioni AP, Peri G, et al. Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004; 110(16): 2349–2354.
  37. Kimura S, Inagaki H, Haraguchi Go, et al. Relationships of Elevated Systemic Pentraxin-3 Levels With High-Risk Coronary Plaque Components and Impaired Myocardial Perfusion After Percutaneous Coronary Intervention in Patients With ST-Elevation Acute Myocardial Infarction. Circulation Journal. 2014: 159–169.
  38. Guo R, Li Y, Wen J, et al. Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention. Cardiology. 2014; 129(3): 178–188.
  39. Matsubara J, Sugiyama S, Nozaki T, et al. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction. J Am Heart Assoc. 2014; 3(4).
  40. Kaess BM, Vasan RS. Heart failure: pentraxin 3—a marker of diastolic dysfunction and HF? Nat Rev Cardiol. 2011; 8(5): 246–248.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl